Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $139.15, for a total transaction of $27,830.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up $0.08 during trading hours on Wednesday, hitting $140.63. 504,987 shares of the company’s stock traded hands, compared to its average volume of 505,568. Jazz Pharmaceuticals PLC has a 12 month low of $101.44 and a 12 month high of $163.75. The firm has a market capitalization of $8,393.07, a price-to-earnings ratio of 17.57, a P/E/G ratio of 0.90 and a beta of 0.98. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.

JAZZ has been the topic of several research reports. FBR & Co initiated coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 price objective on the stock. Royal Bank of Canada dropped their price objective on shares of Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $165.00 price objective on the stock. Finally, UBS reiterated a “buy” rating and set a $172.00 price objective (down previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $181.28.

Several large investors have recently made changes to their positions in JAZZ. US Bancorp DE boosted its holdings in shares of Jazz Pharmaceuticals by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 368 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Jazz Pharmaceuticals by 9.8% in the second quarter. Russell Investments Group Ltd. now owns 16,576 shares of the specialty pharmaceutical company’s stock valued at $2,578,000 after acquiring an additional 1,483 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $211,000. World Asset Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after acquiring an additional 27 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $249,000. Institutional investors own 91.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) EVP Sells 200 Shares of Stock” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/13/insider-selling-jazz-pharmaceuticals-plc-jazz-evp-sells-200-shares-of-stock.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.